Julie A Bettinger1, David W Scheifele2, Scott A Halperin3, Wendy Vaudry4, Jamie Findlow5, Ray Borrow5, Duccio Medini6, Raymond Tsang7. 1. Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada. Electronic address: jbettinger@cfri.ca. 2. Vaccine Evaluation Center, BC Children's Hospital and the University of British Columbia, Vancouver V5Z4H4, Canada. 3. Canadian Center for Vaccinology, IWK Health Centre and Dalhousie University, Halifax B3K6R8, Canada. 4. Stollery Children's Hospital and University of Alberta, Edmonton T6G1C9, Canada. 5. Vaccine Evaluation Unit, Health Protection Agency, Manchester M13 9WZ, UK. 6. Novartis Vaccines, Siena 53100, Italy. 7. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg R3E3R2, Canada.
Abstract
BACKGROUND: In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009. METHODS: IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA). RESULTS: In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46-78%), with 26%, 29% and 11% of strains covered by one, two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA. The majority of strains for clonal complex (cc) 41/44 and cc60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154) was 95% and 100%, respectively. CONCLUSIONS: 4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.
BACKGROUND: In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009. METHODS: IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA). RESULTS: In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46-78%), with 26%, 29% and 11% of strains covered by one, two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA. The majority of strains for clonal complex (cc) 41/44 and cc60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA. Coverage for two prevalent strains (sequence type (ST)-269 and ST-154) was 95% and 100%, respectively. CONCLUSIONS: 4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.
Authors: Gary W Zlotnick; Thomas R Jones; Paul Liberator; Li Hao; Shannon Harris; Lisa K McNeil; Duzhang Zhu; John Perez; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson Journal: Hum Vaccin Immunother Date: 2014-11-01 Impact factor: 3.452